Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cellular Oncology
Erschienen in: Cellular Oncology 2/2016

20.01.2016 | Review

PSA and beyond: alternative prostate cancer biomarkers

verfasst von: Sharanjot Saini, Ph.D.

Erschienen in: Cellular Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The use of biomarkers for prostate cancer screening, diagnosis and prognosis has the potential to improve the clinical management of the patients. Owing to inherent limitations of the biomarker prostate-specific antigen (PSA), intensive efforts are currently directed towards a search for alternative prostate cancer biomarkers, particularly those that can predict disease aggressiveness and drive better treatment decisions.

Methods

A literature search of Medline articles focused on recent and emerging advances in prostate cancer biomarkers was performed. The most promising biomarkers that have the potential to meet the unmet clinical needs in prostate cancer patient management and/or that are clinically implemented were selected.

Conclusions

With the advent of advanced genomic and proteomic technologies, we have in recent years seen an enormous spurt in prostate cancer biomarker research with several promising alternative biomarkers being discovered that show an improved sensitivity and specificity over PSA. The new generation of biomarkers can be tested via serum, urine, or tissue-based assays that have either received regulatory approval by the US Food and Drug Administration or are available as Clinical Laboratory Improvement Amendments-based laboratory developed tests. Additional emerging novel biomarkers for prostate cancer, including circulating tumor cells, microRNAs and exosomes, are still in their infancy. Together, these biomarkers provide actionable guidance for prostate cancer risk assessment, and are expected to lead to an era of personalized medicine.
Literatur
1.
R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2015. CA Cancer J. Clin. 65, 5–29 (2015)CrossRefPubMed
2.
M.K. Fong, R. Hare, A. Jarkowski, A new era for castrate resistant prostate cancer: a treatment review and update. J. Oncol. Pharm. Pract. 18, 343–354 (2012)CrossRefPubMed
3.
D.N. Rodrigues, L.M. Butler, D.L. Estelles, J.S. de Bono, Molecular pathology and prostate cancer therapeutics: from biology to bedside. J. Pathol. 232, 178–184 (2013)
4.
R.D. Loberg, C.J. Logothetis, E.T. Keller, K.J. Pienta, Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J. Clin. Oncol. 23, 8232–8241 (2005)CrossRefPubMed
5.
J. Romero Otero, B. Garcia Gomez, F. Campos Juanatey, K.A. Touijer, Prostate cancer biomarkers: an update. Urol. Oncol. 32, 252–260 (2014)CrossRefPubMed
6.
H. Lilja, Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancer. Clin. Chem. 54, 1248–1249 (2008)CrossRefPubMed
7.
H. Lilja, D. Ulmert, A.J. Vickers, Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 8, 268–278 (2008)CrossRefPubMed
8.
K.C. Cary, M.R. Cooperberg, Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther. Adv. Urol. 5, 318–329 (2013)CrossRefPubMedPubMedCentral
9.
10.
G.T. Mellinger, D. Gleason, J. Bailar 3rd, The histology and prognosis of prostatic cancer. J. Urol. 97, 331–337 (1967)PubMed
11.
12.
J.A. Squire, P.C. Park, M. Yoshimoto, J. Alami, J.L. Williams, A. Evans et al., Prostate cancer as a model system for genetic diversity in tumors. Adv. Cancer Res. 112, 183–216 (2011)CrossRefPubMed
13.
J.R. Schoenborn, P. Nelson, M. Fang, Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin. Cancer Res. 19, 4058–4066 (2013)CrossRefPubMedPubMedCentral
14.
S.E. Ilyin, S.M. Belkowski, C.R. Plata-Salaman, Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol. 22, 411–416 (2004)CrossRefPubMed
15.
J.R. Prensner, M.A. Rubin, J.T. Wei, A.M. Chinnaiyan, Beyond PSA: the next generation of prostate cancer biomarkers. Sci. Transl. Med. 4, 127rv123 (2012)
16.
17.
F.C. Lowe, S.J. Trauzzi, Prostatic acid phosphatase in 1993. Its limited clinical utility. Urol. Clin. North Am. 20, 589–595 (1993)PubMed
18.
C.J. Ercole, P.H. Lange, M. Mathisen, R.K. Chiou, P.K. Reddy, R.L. Vessella, Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J. Urol. 138, 1181–1184 (1987)PubMed
19.
20.
21.
Y. Mazaheri, A. Shukla-Dave, A. Muellner, H. Hricak, MRI of the prostate: clinical relevance and emerging applications. J. Magn. Reson. Imaging 33, 258–274 (2011)CrossRefPubMed
22.
K. Bensalah, F. Montorsi, S.F. Shariat, Challenges of cancer biomarker profiling. Eur. Urol. 52, 1601–1609 (2007)CrossRefPubMed
23.
J. Hernandez, I.M. Thompson, Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 101, 894–904 (2004)CrossRefPubMed
24.
I.M. Thompson, D.K. Pauler, P.J. Goodman, C.M. Tangen, M.S. Lucia, H.L. Parnes et al., Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 350, 2239–2246 (2004)CrossRefPubMed
25.
W.J. Catalona, D.S. Smith, D.K. Ornstein, Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277, 1452–1455 (1997)CrossRefPubMed
26.
L.C. Walter, D. Bertenthal, K. Lindquist, B.R. Konety, PSA screening among elderly men with limited life expectancies. JAMA 296, 2336–2342 (2006)CrossRefPubMed
27.
D.D. Brooks, A. Wolf, R.A. Smith, C. Dash, I. Guessous, Prostate cancer screening 2010: updated recommendations from the American Cancer Society. J. Natl. Med. Assoc. 102, 423–429 (2010)CrossRefPubMed
28.
A.M. Wolf, R.C. Wender, R.B. Etzioni, I.M. Thompson, A.V. D’Amico, R.J. Volk et al., American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J. Clin. 60, 70–98 (2010)CrossRefPubMed
29.
A.V. D’Amico, M.H. Chen, K.A. Roehl, W.J. Catalona, Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N. Engl. J. Med. 351, 125–135 (2004)CrossRefPubMed
30.
R. Etzioni, A. Tsodikov, A. Mariotto, A. Szabo, S. Falcon, J. Wegelin et al., Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 19, 175–181 (2008)CrossRefPubMedPubMedCentral
31.
A. Christensson, T. Bjork, O. Nilsson, U. Dahlen, M.T. Matikainen, A.T. Cockett et al., Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J. Urol. 150, 100–105 (1993)PubMed
32.
W.J. Catalona, A.W. Partin, K.M. Slawin, M.K. Brawer, R.C. Flanigan, A. Patel et al., Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279, 1542–1547 (1998)CrossRefPubMed
33.
M.A. Khan, L.J. Sokoll, D.W. Chan, L.A. Mangold, P. Mohr, S.D. Mikolajczyk et al., Clinical utility of proPSA and “benign” PSA when percent free PSA is less than 15 %. Urology 64, 1160–1164 (2004)CrossRefPubMed
34.
S. Hori, J.S. Blanchet, J. McLoughlin, From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int. 112, 717–728 (2013)CrossRefPubMed
35.
S.D. Mikolajczyk, K.M. Marker, L.S. Millar, A. Kumar, M.S. Saedi, J.K. Payne et al., A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 61, 6958–6963 (2001)PubMed
36.
T.Y. Chan, S.D. Mikolajczyk, K. Lecksell, M.J. Shue, H.G. Rittenhouse, A.W. Partin et al., Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 62, 177–181 (2003)CrossRefPubMed
37.
I. Heidegger, H. Klocker, E. Steiner, V. Skradski, M. Ladurner, R. Pichler et al., [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer Prostatic Dis. 17, 70–74 (2014)CrossRefPubMed
38.
M. Lazzeri, A. Abrate, G. Lughezzani, G.M. Gadda, M. Freschi, F. Mistretta et al., Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination. Urology 83, 606–612 (2014)CrossRefPubMed
39.
M. Lazzeri, A. Haese, A. Abrate, A. de la Taille, J.P. Redorta, T. McNicholas et al., Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int. 112, 313–321 (2013)CrossRefPubMed
40.
G. Guazzoni, L. Nava, M. Lazzeri, V. Scattoni, G. Lughezzani, C. Maccagnano et al., Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur. Urol. 60, 214–222 (2011)CrossRefPubMed
41.
A. Houlgatte, S. Vincendeau, F. Desfemmes, J. Ramirez, N. Benoist, K. Bensalah et al., Use of [-2] pro PSA and phi index for early detection of prostate cancer: a prospective of 452 patients. Prog. Urol. 22, 279–283 (2012)CrossRefPubMed
42.
L.J. Sokoll, M.G. Sanda, Z. Feng, J. Kagan, I.A. Mizrahi, D.L. Broyles et al., A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol. Biomarkers Prev. 19, 1193–1200 (2010)CrossRefPubMedPubMedCentral
43.
M.J. Bussemakers, A. van Bokhoven, G.W. Verhaegh, F.P. Smit, H.F. Karthaus, J.A. Schalken et al., DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 59, 5975–5979 (1999)PubMed
44.
J.B. de Kok, G.W. Verhaegh, R.W. Roelofs, D. Hessels, L.A. Kiemeney, T.W. Aalders et al., DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 62, 2695–2698 (2002)PubMed
45.
M. Auprich, A. Bjartell, F.K. Chun, A. de la Taille, S.J. Freedland, A. Haese et al., Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur. Urol. 60, 1045–1054 (2011)CrossRefPubMed
46.
E.D. Crawford, K.O. Rove, E.J. Trabulsi, J. Qian, K.P. Drewnowska, J.C. Kaminetsky et al., Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J. Urol. 188, 1726–1731 (2012)CrossRefPubMed
47.
V. Vlaeminck-Guillem, A. Ruffion, J. Andre, M. Devonec, P. Paparel, Urinary prostate cancer 3 test: toward the age of reason? Urology 75, 447–453 (2010)CrossRefPubMed
48.
I.L. Deras, S.M. Aubin, A. Blase, J.R. Day, S. Koo, A.W. Partin et al., PCA3: a molecular urine assay for predicting prostate biopsy outcome. J. Urol. 179, 1587–1592 (2008)CrossRefPubMed
49.
50.
G.H. Leyten, D. Hessels, S.A. Jannink, F.P. Smit, H. de Jong, E.B. Cornel et al., Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur. Urol. 65, 534–542 (2014)CrossRefPubMed
51.
52.
S.S. Salami, F. Schmidt, B. Laxman, M.M. Regan, D.S. Rickman, D. Scherr et al., Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol. Oncol. 31, 566–571 (2013)CrossRefPubMedPubMedCentral
53.
D. Knezevic, A.D. Goddard, N. Natraj, D.B. Cherbavaz, K.M. Clark-Langone, J. Snable et al., Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics 14, 690 (2013)CrossRefPubMedPubMedCentral
54.
P. Blume-Jensen, D.M. Berman, D.L. Rimm, M. Shipitsin, M. Putzi, T.P. Nifong et al., Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin. Cancer Res. 21, 2591–2600 (2015)CrossRefPubMed
55.
J.N. Cornu, G. Cancel-Tassin, C. Egrot, C. Gaffory, F. Haab, O. Cussenot, Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate 73, 242–249 (2013)CrossRefPubMed
56.
M.R. Cooperberg, J.P. Simko, J.E. Cowan, J.E. Reid, A. Djalilvand, S. Bhatnagar et al., Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J. Clin. Oncol. 31, 1428–1434 (2013)CrossRefPubMed
57.
J. Cuzick, D.M. Berney, G. Fisher, D. Mesher, H. Moller, J.E. Reid et al., Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br. J. Cancer 106, 1095–1099 (2012)CrossRefPubMedPubMedCentral
58.
S.J. Freedland, L. Gerber, J. Reid, W. Welbourn, E. Tikishvili, J. Park et al., Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 86, 848–853 (2013)CrossRefPubMedPubMedCentral
59.
R.L. Parr, J. Mills, A. Harbottle, J.M. Creed, G. Crewdson, B. Reguly et al., Mitochondria, prostate cancer, and biopsy sampling error. Discov. Med. 15, 213–220 (2013)PubMed
60.
M.L. Verschoor, R. Ungard, A. Harbottle, J.P. Jakupciak, R.L. Parr, G. Singh, Mitochondria and cancer: past, present, and future. Biomed Res Int 2013, 612369 (2013)CrossRefPubMedPubMedCentral
61.
K. Robinson, J. Creed, B. Reguly, C. Powell, R. Wittock, D. Klein et al., Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer Prostatic Dis. 13, 126–131 (2010)CrossRefPubMed
62.
S. Carlsson, A. Maschino, F. Schroder, C. Bangma, E.W. Steyerberg, T. van der Kwast et al., Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. Eur. Urol. 64, 693–699 (2013)CrossRefPubMedPubMedCentral
63.
J.D. Voigt, S.M. Zappala, E.D. Vaughan, A.J. Wein, The Kallikrein panel for prostate cancer screening: its economic impact. Prostate 74, 250–259 (2014)CrossRefPubMed
64.
A. Sreekumar, L.M. Poisson, T.M. Rajendiran, A.P. Khan, Q. Cao, J. Yu et al., Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910–914 (2009)CrossRefPubMedPubMedCentral
65.
K. Badani, D.J. Thompson, C. Buerki, E. Davicioni, J. Garrison, M. Ghadessi et al., Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget 4, 600–609 (2013)CrossRefPubMedPubMedCentral
66.
E.D. Crawford, K. Ventii, N.D. Shore, New biomarkers in prostate cancer. Oncology (Williston Park) 28, 135–142 (2014)
67.
M.A. Rubin, M. Zhou, S.M. Dhanasekaran, S. Varambally, T.R. Barrette, M.G. Sanda et al., alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287, 1662–1670 (2002)CrossRefPubMed
68.
M.A. Rubin, T.A. Bismar, O. Andren, L. Mucci, R. Kim, R. Shen et al., Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol. Biomarkers Prev. 14, 1424–1432 (2005)CrossRefPubMed
69.
Z. Jiang, G.R. Fanger, B.A. Woda, B.F. Banner, P. Algate, K. Dresser et al., Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases. Hum. Pathol. 34, 792–796 (2003)CrossRefPubMed
70.
P. Cairns, K. Okami, S. Halachmi, N. Halachmi, M. Esteller, J.G. Herman et al., Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57, 4997–5000 (1997)PubMed
71.
B.S. Carver, C. Chapinski, J. Wongvipat, H. Hieronymus, Y. Chen, S. Chandarlapaty et al., Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575–586 (2011)CrossRefPubMedPubMedCentral
72.
73.
K. Sircar, M. Yoshimoto, F.A. Monzon, I.H. Koumakpayi, R.L. Katz, A. Khanna et al., PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J. Pathol. 218, 505–513 (2009)CrossRefPubMed
74.
A. Krohn, T. Diedler, L. Burkhardt, P.S. Mayer, C. De Silva, M. Meyer-Kornblum et al., Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am. J. Pathol. 181, 401–412 (2012)CrossRefPubMed
75.
K.A. Leinonen, O.R. Saramaki, B. Furusato, T. Kimura, H. Takahashi, S. Egawa et al., Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol. Biomarkers Prev. 22, 2333–2344 (2013)CrossRefPubMedPubMedCentral
76.
M. Yoshimoto, A.M. Joshua, I.W. Cunha, R.A. Coudry, F.P. Fonseca, O. Ludkovski et al., Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod. Pathol. 21, 1451–1460 (2008)CrossRefPubMed
77.
L.H. Broersen, G.W. van Pelt, R.A. Tollenaar, W.E. Mesker, Clinical application of circulating tumor cells in breast cancer. Cell. Oncol. 37, 9–15 (2014)
78.
D.C. Danila, G. Heller, G.A. Gignac, R. Gonzalez-Espinoza, A. Anand, E. Tanaka et al., Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 13, 7053–7058 (2007)CrossRefPubMed
79.
M.J. Kim, N.Y. Choi, E.K. Lee, M.S. Kang, Identification of novel markers that outperform EpCAM in quantifying circulating tumor cells. Cell. Oncol. 37, 235–243 (2014)
80.
G. Attard, J.F. Swennenhuis, D. Olmos, A.H. Reid, E. Vickers, R. A’Hern et al., Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69, 2912–2918 (2009)CrossRefPubMed
81.
J.S. de Bono, H.I. Scher, R.B. Montgomery, C. Parker, M.C. Miller, H. Tissing et al., Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302–6309 (2008)CrossRefPubMed
82.
83.
A. Gordanpour, R.K. Nam, L. Sugar, A. Seth, MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics. Prostate Cancer Prostatic Dis. 15, 314–319 (2012)CrossRefPubMed
84.
85.
86.
S. Saini, S. Majid, S. Yamamura, L. Tabatabai, S.O. Suh, V. Shahryari et al., Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin. Cancer Res. 17, 5287–5298 (2011)CrossRefPubMed
87.
I. Giusti, V. Dolo, Extracellular vesicles in prostate cancer: new future clinical strategies? Biomed Res Int 2014, 561571 (2014)PubMedPubMedCentral
88.
Y. Xi, G. Nakajima, E. Gavin, C.G. Morris, K. Kudo, K. Hayashi et al., Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13, 1668–1674 (2007)CrossRefPubMedPubMedCentral
89.
J.A. Weber, D.H. Baxter, S. Zhang, D.Y. Huang, K.H. Huang, M.J. Lee et al., The microRNA spectrum in 12 body fluids. Clin. Chem. 56, 1733–1741 (2010)CrossRefPubMed
90.
S. Dijkstra, P.F. Mulders, J.A. Schalken, Clinical use of novel urine and blood based prostate cancer biomarkers: a review. Clin. Biochem. 47, 889–896 (2014)CrossRefPubMed
91.
J. Szczyrba, E. Loprich, S. Wach, V. Jung, G. Unteregger, S. Barth et al., The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol. Cancer Res. 8, 529–538 (2010)CrossRefPubMed
92.
A. Schaefer, M. Jung, H.J. Mollenkopf, I. Wagner, C. Stephan, F. Jentzmik et al., Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 126, 1166–1176 (2010)PubMed
93.
P.S. Mitchell, R.K. Parkin, E.M. Kroh, B.R. Fritz, S.K. Wyman, E.L. Pogosova-Agadjanyan et al., Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 105, 10513–10518 (2008)CrossRefPubMedPubMedCentral
94.
F. Moltzahn, A.B. Olshen, L. Baehner, A. Peek, L. Fong, H. Stoppler et al., Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 71, 550–560 (2011)CrossRefPubMedPubMedCentral
95.
R.J. Bryant, T. Pawlowski, J.W. Catto, G. Marsden, R.L. Vessella, B. Rhees et al., Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 106, 768–774 (2012)CrossRefPubMedPubMedCentral
96.
S. Mathivanan, H. Ji, R.J. Simpson, Exosomes: extracellular organelles important in intercellular communication. J Proteomics 73, 1907–1920 (2010)CrossRefPubMed
97.
D. Duijvesz, T. Luider, C.H. Bangma, G. Jenster, Exosomes as biomarker treasure chests for prostate cancer. Eur. Urol. 59, 823–831 (2011)CrossRefPubMed
98.
G. Tavoosidana, G. Ronquist, S. Darmanis, J. Yan, L. Carlsson, D. Wu et al., Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 108, 8809–8814 (2011)CrossRefPubMedPubMedCentral
99.
J. Nilsson, J. Skog, A. Nordstrand, V. Baranov, L. Mincheva-Nilsson, X.O. Breakefield et al., Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br. J. Cancer 100, 1603–1607 (2009)CrossRefPubMedPubMedCentral
100.
S. Khan, J.M. Jutzy, M.M. Valenzuela, D. Turay, J.R. Aspe, A. Ashok et al., Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS ONE 7, e46737 (2012)CrossRefPubMedPubMedCentral
101.
A. Cannistraci, A.L. Di Pace, R. De Maria, D. Bonci, MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients’ samples. Biomed Res Int 2014, 146170 (2014)CrossRefPubMedPubMedCentral
102.
M.A. Cortez, C. Bueso-Ramos, J. Ferdin, G. Lopez-Berestein, A.K. Sood, G.A. Calin, MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 8, 467–477 (2011)CrossRefPubMedPubMedCentral
Metadaten
Titel
PSA and beyond: alternative prostate cancer biomarkers
verfasst von
Sharanjot Saini, Ph.D.
Publikationsdatum
20.01.2016
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 2/2016
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-016-0268-6

Weitere Artikel der Ausgabe 2/2016

Cellular Oncology 2/2016 Zur Ausgabe

Original Paper

Down-regulation of osteopontin mediates a novel mechanism underlying the cytostatic activity of TGF-β

Original Paper

Human IGF1 pro-forms induce breast cancer cell proliferation via the IGF1 receptor

Original Paper

Identification of miR-139-5p as a saliva biomarker for tongue squamous cell carcinoma: a pilot study

Original Paper

Efficacy of doxorubicin-transferrin conjugate in apoptosis induction in human leukemia cells through reactive oxygen species generation

Original Paper

Altered Lamin A/C splice variant expression as a possible diagnostic marker in breast cancer

Original Paper

MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Open Access 22.02.2024 | Pathologie | Originalien

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

21.02.2024 | Thrombozytopenie | CME

Knochenmarkhistologie bei Zytopenien
Beitrag zur hämatologischen Differenzialdiagnostik

Open Access 21.02.2024 | Fettleber | Originalien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien
Automatische Quantifizierung von Leberverfettung